Nathan H Fowler, MD
Evens AM et al. A 3-arm randomized phase II trial with bendamustine/rituximab therapy in untreated high risk (HR) follicular lymphoma (FL): Bortezomib induction or novel IMiD® continuation (BIONIC) study from the ECOG-ACRIN Cancer Research Group. Proc ASH 2017;Abstract 482.
Fowler N et al. RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma. Proc ASCO 2018;Abstract 7500.
Fowler N et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: An open-label, phase 2 trial. Lancet Oncol 2014;15(12):1311-8. Abstract
Fowler N et al. High response rates with lenalidomide plus rituximab for untreated, indolent, B cell NHL. Proc ICML 2011;Abstract 137.
Hiddemann W et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM Study: Influence of chemotherapy on efficacy and safety. J Clin Oncol 2018;[Epub ahead of print]. Abstract
Marcus R et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017;377(14):1331-44. Abstract
Rummel MJ et al. Four versus two years of rituximab maintenance (R-maintenance) following bendamustine plus rituximab (B-R): Initial results of a prospective, randomized multicenter Phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study). Proc ASH 2017;Abstract 483.
Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203-10. Abstract
Salles GA et al. Long term follow-up of the PRIMA study: Half of patients receiving rituximab maintenance remain progression free at 10 years. Proc ASH 2017;Abstract 486.
Andrew D Zelenetz, MD, PhD
Cheson B et al. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: Updated results of the GADOLIN Study. Proc ASH 2016;Abstract 615.
Fischer T et al. Natural history of hypogammaglobulinemia in patients with follicular lymphoma and the impact of anti-CD20-based therapy. Proc ASH 2017;Abstract 4054.
Kahl BS et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group Protocol E4402. J Clin Oncol 2014;32(28):3096-102. Abstract
Marcus R et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017;377(14):1331-44. Abstract
Marcus R et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: Primary results of the randomized phase 3 GALLIUM study. Proc ASH 2016;Abstract 6.
Morschhauser F et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26(32):5156-64. Abstract
Salles GA et al. Long term follow-up of the PRIMA study: Half of patients receiving rituximab maintenance remain progression free at 10 years. Proc ASH 2017;Abstract 486.
Vidal L et al. Rituximab maintenance improves overall survival of patients with follicular lymphoma — Individual patient data meta-analysis. Eur J Cancer 2017;76:216-25. Abstract
Stephen M Ansell, MD, PhD
Davids MS et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 2017;35(8):826-33. Abstract
Dreyling M et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 2017;35(35):3898-905. Abstract
Gopal AK et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18. Abstract
Gribben JG et al. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 2015;33(25):2803-11. Abstract
Kershaw MH et al. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2016;13(8):525-41. Abstract
Leonard JP et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol 2015;33(31):3635-40. Abstract
Magee MS, Snook AE. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. Discov Med 2014;18(100):265-71. Abstract
Majchrzak A et al. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: Current knowledge and clinical significance. Molecules 2014;19(9):14304-15. Abstract
Morschhauser F et al. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients with relapsed/refractory non-Hodgkin lymphoma. Proc ASCO 2014;Abstract 8519.
Palanca-Wessels MC et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: A phase 1 study. Lancet Oncol 2015;16(6):704-15. Abstract
Roberts AW et al. Venetoclax in patients with previously treated chronic lymphocytic leukemia. Clin Cancer Res 2017;23(16):4527-33. Abstract
Salles G et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study. Haematologica 2017;102(4):e156-9. Abstract
Schuster SJ et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 2017;377(26):2545-54. Abstract
Strout MP. Sugar-coated signaling in follicular lymphoma. Blood 2015;126(16):1871-2. Abstract
Zinzani PL et al. Phase 2 study of venetoclax plus rituximab or randomized ven plus bendamustine + rituximab (BR) versus BR in patients with relapsed/refractory follicular lymphoma: Interim data. Proc ASH 2016;Abstract 617.
Laurie H Sehn, MD, MPH
Al-Tourah AJ et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 2008;26(32):5165-9. Abstract
Bodet-Milin C et al. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 2008;93(3):471-2. Abstract
Casulo C et al. Autologous transplantation in follicular lymphoma with early therapy failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research analysis. Biol Blood Marrow Transplant 2018;24(6):1163-71. Abstract
Casulo C et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study. J Clin Oncol 2015;33(23):2516-22. Abstract
Cheson B et al. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: Updated results of the GADOLIN study. Proc ASH 2016;Abstract 615.
Jurinovic V et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: A follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant 2018;24(6):1172-9. Abstract
Link BK et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 2013;31(26):3272-8. Abstract
Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol 2011;29(14):1827-34. Abstract
Noy A et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2009;20(3):508-12. Abstract
Sarkozy C et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol 2016;34(22):2575-82. Abstract
Schöder H et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2005;23(21):4643-51. Abstract
Sehn LH et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncology 2016;17(8):1081-93. Abstract
Villa D et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: A report of the Canadian Blood and Marrow Transplant Group. J Clin Oncol 2013;31(9):1164-71. Abstract
Wagner-Johnston ND et al. Outcomes of transformed follicular lymphoma in the modern era: A report from the National LymphoCare Study (NLCS). Blood 2015;126(7):851-7. Abstract